Prediabetes in Patients Treated With Antipsychotic Drugs

Prediabetes in Patients Treated With Antipsychotic Drugs

J Clin Psychiatry, Online ahead of print: December 27, 2011

In 2010, American Diabetes Association (ADA) proposed that individuals with fasting glucose level of 100–125 mg/dL (5.6–6.9 mmol/L) or glucose level of 140–199 mg/dL (7.8–11.0 mmol/L) 2 hours after a 75-g oral glucose tolerance test or hemoglobin A1c 5.7%–6.4% be classified as prediabetic, indicating increased risk for the emergence of diabetes mellitus.


Method:
- The 2010 ADA criteria were applied to a large, consecutive, single-site European cohort of 783 adult psychiatric inpatients (mean age: 37.6 years) without a history of diabetes who were receiving antipsychotics.
- All patients in this cross-sectional study underwent measurement of body mass index (BMI), waist circumference, oral glucose tolerance test, and fasting insulin and lipids from November 2003 through July 2007.

Results:
- 413 patients (52.8%) had normal glucose tolerance,
- 290 (37.0%) had prediabetes, and
- 80 (10.2%) had diabetes mellitus.

- The fasting glucose and/or hemoglobin A1c criteria were met by 89.7% of prediabetic patients.
- A statistically significant intergroup gradient from normal glucose tolerance to prediabetes and from prediabetes to diabetes mellitus was observed for waist circumference, triglycerides, fasting insulin levels, and frequency of metabolic syndrome (P = .02 to P < .0001).
- Only 19/290 prediabetic patients (6.6%) met the 2010 ADA criteria for treatment with metformin.

Conclusions:
Prediabetes is highly prevalent in adults treated with antipsychotic drugs and correlates with markers of increased intraabdominal adiposity, enhanced lipolysis, and insulin resistance. Criteria for using metformin to prevent the emergence of diabetes mellitus may need to be revised for this population.